XML 20 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 23,250,762 $ 57,632,693
Short-term investments 96,435,585 105,357,277
Accounts receivable 17,455,108 7,333,059
Prepaid expenses and other current assets 1,391,252 917,257
Prepaid expenses and other current assets from affiliated entity 1,697,213 610,652
Total current assets 140,229,920 171,850,938
Fixed assets, net 8,990,714 7,306,695
Investment in affiliated entity- GeneOne 20,758,587 14,941,277
Investment in affiliated entity - PLS 4,537,761 5,045,915
Intangible assets, net 8,036,874 3,905,860
Goodwill 10,513,371 10,113,371
Other assets 1,482,066 676,803
Total assets 194,549,293 213,840,859
Current liabilities:    
Accounts payable and accrued expenses 16,183,976 13,064,899
Accounts payable and accrued expenses due to affiliated entity 493,420 165,047
Accrued clinical trial expenses 7,216,266 2,600,483
Common stock warrants 1,812,502 1,301,138
Deferred revenue 14,829,634 13,449,768
Deferred revenue from affiliated entity 438,542 504,442
Deferred rent 400,200 380,629
Total current liabilities 41,374,540 31,466,406
Deferred revenue, net of current portion 365,687 103,074
Deferred revenue from affiliated entity, net of current portion 180,444 677,371
Deferred rent, net of current portion 5,474,834 5,485,313
Deferred tax liabilities 175,642 175,642
Total liabilities 47,571,147 37,907,806
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 73,967 72,218
Additional paid-in capital 552,753,321 534,004,564
Accumulated deficit (408,604,765) (361,097,896)
Accumulated other comprehensive income 2,659,354 2,708,339
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 146,881,877 175,687,225
Non-controlling interest 96,269 245,828
Total stockholders’ equity 146,978,146 175,933,053
Total liabilities and stockholders’ equity $ 194,549,293 $ 213,840,859